Intellia Therapeutics, Inc. (NTLA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Intellia Therapeutics, Inc. (NTLA) closed at USD 11.43 on 2026-10-14, a change of -18.1 % over the past year, with a market capitalization of USD 1.59B.

Intellia Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Intellia Therapeutics, Inc. key figures

Previous close

USD 11.43 (2026-10-14)

1-year change

-18.1 %

Market cap

USD 1.59B

Enterprise value

USD 1.22B

P/E ratio (trailing)

-3.56

P/E ratio (forward)

-4.42

EPS (trailing)

-3.19

EPS (forward)

-2.56

PEG ratio

n/a

Price to book

2.18

Revenue growth

-46.2 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.08

Employees

377

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Intellia Therapeutics, Inc. and compare it with other stocks.